Skip to content

WHWK WHWK Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$115.5K

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Reported directly by WHWK in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's payments of stock issuance costs?
WHWK (WHWK) reported payments of stock issuance costs of $0 in Q1 2026.
How has WHWK's payments of stock issuance costs changed year-over-year?
WHWK's payments of stock issuance costs decreased by 100.0% year-over-year, from $4.82M to $0.
What is the long-term trend for WHWK's payments of stock issuance costs?
Over 3 years (2021 to 2024), WHWK's payments of stock issuance costs has grown at a -100.0% compound annual growth rate (CAGR), from $9.62M to $0.
What does payments of stock issuance costs mean?
This metric tracks the direct cash expenditures incurred in connection with the issuance of equity securities, such as underwriting fees, legal expenses, and registration costs. These costs represent the friction associated with raising capital from public or private markets. Investors monitor this to assess the efficiency of the company's capital-raising processes.